News

Grenova Announces Katherine Marrs as New CEO to Drive Innovation and Growth

Grenova, an industry leader in sustainable laboratory solutions, has appointed Katherine Marrs as its new Chief Executive Officer (CEO). Marrs succeeds Lane Major, who has served as CEO since 2023 and will continue to support Grenova as a member of the Board of Directors.

Marrs has been instrumental in driving Grenova’s growth strategy as the company’s Chief Commercial Officer for the past 16 months. Her leadership has been pivotal in expanding Grenova’s presence in the European market and enhancing its commitment to sustainability within the Life Sciences industry.

“We are at an exciting juncture, and I am honored to lead Grenova as we drive forward,” said Marrs. “I look forward to building on our team’s accomplishments, enhancing our innovative product portfolio, advancing our automation and integration capabilities, and furthering our commitment to helping laboratories reduce their environmental footprint.”

Lane Major expressed his confidence in Marrs’ ability to lead Grenova into its next chapter. “Katherine has demonstrated remarkable vision and leadership during her time as Chief Commercial Officer. Her deep understanding of our business and commitment to innovation make her the perfect choice to lead Grenova.”

Ted Lundberg, Chairman of the Board of Directors for Grenova and Co-Founder of Peloton Equity, Grenova’s majority owner, said, “Katherine has shown remarkable skill in guiding Grenova’s commercial strategy and building a solid foundation for the company’s future. Her dedication, expertise, and strategic focus have proven invaluable, and we look forward to her continued success as CEO.”

As Grenova continues expanding its solutions, Marrs will leverage her expertise to enhance the company’s position in the market, foster partnerships that align with Grenova’s mission, and drive initiatives that further its dedication to environmental and economic responsibility.

 

Read more here.

Recent News

10/22/2026

Lilly breaks ground in Richmond to expand American manufacturing of next-generation cancer medicines, advancing its build-out of 10 new U.S. sites since 2020

Eli Lilly and Company (NYSE: LLY) broke ground today on a new $5 billion manufacturing facility just west of Richmond, Virginia, in Goochland County, one of 10 new U.S. manufacturing sites announced since 2020 and one of five among them that will produce active pharmaceutical ingredients (API). As part of the company’s more than $50 …

10/21/2026

United Therapeutics Expands Organ Manufacturing Capabilities with Opening of Third Designated Pathogen-Free Xenograft Production Facility

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the opening of its third Designated Pathogen-Free (DPF) facility, The Dr. Bartley P. Griffith and Dr. Robert A. Montgomery Xenograft Production Facility, in Houston, Texas. United Therapeutics opened its first DPF facility in Christiansburg, Va. in 2024 to produce xenografts for ongoing clinical trials. …

10/20/2026

Supernus Reaches Key Milestone Toward Proposed Merger with Indivior Following Shareholder Approval

Supernus Pharmaceuticals, Inc. welcomed the decisive backing of shareholders today, who formally voted to approve the pending all-stock merger of equals. This vote marks an important milestone toward completing the merger announced in August 2026, with closing anticipated on November 2, 2026, subject to customary closing conditions. Following closing, the combined organization will officially commence …